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Abstract
As Bulgaria transitions away from Global Fund grant, robust estimates of the comparative
impact of the various response strategies under consideration are needed to ensure sustained
effectiveness of the tuberculosis (TB) programme. We tailored an established mathematical
model for TB control to the epidemic in Bulgaria to project the likely outcomes of seven inter-
vention scenarios. Under existing programmatic conditions projected forward, the country’s
targets for achieving TB elimination in the coming decades will not be achieved. No interven-
tions under consideration were predicted to accelerate the baseline projected reduction in
epidemiological indicators significantly. Discontinuation of the ‘Open Doors’ program and
activities of non-governmental organisations would result in a marked exacerbation of the
epidemic (increasing incidence in 2035 by 6–8% relative to baseline conditions projected
forward). Changing to a short course regimen for multidrug-resistant TB (MDR-TB)
would substantially decrease MDR-TB mortality (by 21.6% in 2035 relative to baseline con-
ditions projected forward). Changing to ambulatory care for eligible patients would not affect
TB burden but would be markedly cost-saving. In conclusion, Bulgaria faces important chal-
lenges in transitioning to a primarily domestically-financed TB programme. The country
should consider maintaining currently effective programs and shifting towards ambulatory
care to ensure program sustainability.
Introduction
Although the World Health Organisation (WHO) European Region contributes only 3% to
the global tuberculosis (TB) burden, 85% of TB cases in the Region arise in Eastern
European and Central Asian countries [1]. With an incidence rate of 23 cases per 100 000
population in 2016, Bulgaria is one of 18 ‘high priority’ countries for TB control in the
WHO European Region [2]. Multidrug-resistant TB (MDR-TB) remains a problem in the
country and constituted 1.2% of new TB cases and 22.8% of re-treatment TB cases in 2016
[1]. Around 62% of all TB cases in Bulgaria are culture-confirmed, of which ∼86% receive
drug susceptibility testing (DST) [3].
The TB control program in Bulgaria is characterised by extensive involvement of
non-governmental organisations (NGOs), which have been active since 2009. Their TB care
activities include spatial mapping of high-risk groups, screening for active TB and latent TB
infection (LTBI) in high-risk groups, awareness raising and providing support to patients
under treatment. Since 2009, regular community campaigns have been carried out across
the country to raise public awareness about TB, and to offer individuals with respiratory symp-
toms the opportunity to present themselves to public hospitals for free-of-charge TB diagnosis
and treatment (the ‘Open Doors’ program).
Roma communities are among the most important TB risk groups in Bulgaria, accounting
for around 5–10% of the total population, but contributing 30 and 50% respectively of all
reported DS-TB and MDR-TB cases in the country [3]. Diabetes is also a major threat to
TB control efforts in Bulgaria, with the prevalence of type II diabetes among adults in
Bulgaria reaching 8.4% in 2015 [4, 5].
In line with the WHO Sustainable Development Goals (SDGs) and the End TB Strategy
targets [6], Bulgaria aims to achieve TB elimination by 2050. Interim targets aim to reduce in-
cidence and TB-related mortality by 40% in 2025, and by 90 and 95% respectively in 2035.
However, a return to domestically-funded TB programs following the completion of the cur-
rent Global Fund to Fight AIDS, Tuberculosis and Malaria (henceforward ‘the Global Fund’)
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grant, from which several key TB control activities in the country
are financed, may jeopardise the program’s sustainability.
Specifically, the risk of discontinuation of NGO activities and
the Open Doors program could worsen control. As Bulgaria tran-
sitions from external donor support, the country is considering
approaches to strengthen the National Strategic Plan and improve
the sustainability and efficiency of its TB program. To do so, the
country needs reliable estimates of the epidemiological and finan-
cial impact of disease control interventions. Mathematical model-
ling provides a platform to quantify and compare the projected
costs and epidemiological impact of different intervention scen-
arios to guide TB strategic policy [7]. We describe the application
of the ‘AuTuMN’ software platform to TB control and planning
in Bulgaria [7].
Methods
General approach
The AuTuMN software platform has been previously described [7].
The full details of the epidemiological model are described in the
Supplementary Material and summarised as follows. As no indi-
vidual patient data were used, ethical approval was not required.
Given the slow-moving and complex nature of the TB epi-
demic, we aimed for a high degree of consistency with historical
TB dynamics in Bulgaria and permitted a high degree of model
complexity (1199 compartments). To achieve this, we first auto-
matically loaded publicly available data for birth, death, vaccin-
ation and TB-related programmatic measures and then fit
functions to map parameter values to time for these quantities
using polynomial spline functions (Supplementary Section 3).
Demographic model
Individuals first enter the model with the time-variant birth rate
fit to World Bank data (Supplementary Fig. S1), with the propor-
tions of births vaccinated and unvaccinated split according to the
WHO/UNICEF-reported vaccination coverage (Supplementary
Fig. S2). Population-wide natural mortality was also parame-
terised to data from the World Bank (Supplementary Fig. S3)
and applied to all compartments. All compartments were strati-
fied by age, with age groups being: under 5 years, 5 to 15 years,
15 to 25 years and 25 years and above.
Model of Mycobacterium tuberculosis transmission and
progression
From the point of infection onwards, all compartments were also
sub-divided by strain (i.e. DS-TB andMDR-TB). The force of infec-
tion was calculated as the effective number of infectious persons,
which included those yet to present for care, missed (false-negative)
presentations who had not yet re-started care seeking and those
patients who were in very early stage treatment. All paediatric
and smear-negative TB patients were considered to have markedly
reduced infectiousness compared to adults [8–10]. BCG programs
in Bulgaria have varied over the years with revaccination sometimes
performed. However, in the absence of clear evidence for the effect-
iveness of this approach, we assume that BCG-vaccinated children
retain partial immunity from infection until age 15 which wanes
thereafter (Supplementary Section 8). Latent infection was consid-
ered to confer partial immunity, modifying the force of infection
applied to fully susceptible persons; while the relative susceptibil-
ity/immunity attributable to a previously treated disease episode
Table 1. Simulated interventions
Name and description of
intervention
Level of
evidencea
Applicability
of evidence
Primary evidence
source
Coverage
achievable
(by 2020) Model implementation
1. Short course regimen for
MDR-TB
2 Programmatic Van Deun et al. [15]
Piubello et al. [16]
Kuaban et al. [17]
Aung et al., [18]
50% Treatment duration of 12 months
and treatment success rate of 84%
(range 84 to 90%).
2. Scale-up DST coverage in
culture-positive TB cases
5 Clinical Nil 100% Increase proportion of DST in
culture-positive cases from baseline
value of 86% to 100%.
3. Scale-up food vouchers for
all patients under treatment
1 Programmatic Martins et al. [19]
Lutge et al. [20]
Ciobanu et al. [21]
100% Decrease in all treatment outcomes
other than success (i.e. death and
non-death unfavourable outcomes)
by 50% (range 40 to 60%).
4. Transition from inpatient
care to ambulatory care for
smear-negative and
extrapulmonary DS-TB
patients
2 Clinical Bassili et al. [22]
Fitzpatrick et al. [23]
Horter et al. [24]
100% No change to the epidemiological
model. Treatment outcomes are
assumed to be similar for
ambulatory care as compared to
inpatient care.
5. Discontinue Open Doors
program
5 Programmatic Bulgaria NTP 0% Reduce case detection proportion by
8% (range 5 to 12%).
6. Discontinue NGO activities 5 Programmatic Bulgaria NTP 0% Reduce case detection proportion by
8% (range 5 to 12%) in the general
population and by a further 25%
(range 15 to 30%) in the Roma
community.
DST, drug-susceptibility testing; MDR, multidrug-resistant; NGO, non-governmental organisation; NTP, National TB Program; TB, tuberculosis.
aLevel of evidence was graded according to the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. Level 1 indicates strongest evidence, whereas level 5 indicates weakest
evidence.
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was considered highly uncertain and was estimated through the
calibration process.
Following infection, the latent period to active disease was
simulated using two sequential compartments, with infected
persons initially entering a high-risk early latent state before
transitioning to a lower risk late latent compartment [11, 12].
The proportion of infected persons progressing to active disease
from early latency was greater for children than adults [11] and
each new episode of TB was distinguished according to smear
status into smear-positive, smear-negative pulmonary and extra-
pulmonary. Diabetic persons had an approximately threefold
increased risk of progression to active TB following infection
(Supplementary Section 14) [13]. An untreated episode of active
TB was assumed to last for three years, with a greater case fatality
rate for smear-positive than for smear-negative and extrapulmon-
ary TB (Supplementary Section 9) [14].
Population sub-groups
We incorporate three population risk groups of particular import-
ance to the epidemiology of TB in Bulgaria: persons with diabetes
mellitus, the prison population and Roma communities. Diabetes
is implemented as affecting progression rates to disease following
infection, whereas the other two groups are considered to mix
assortatively and have higher contact rates to reflect poorer living
conditions (Fig. S21). The proportion of the population with
diabetes was applied to the oldest age group (25 and above)
only (Supplementary Fig. S9); while the prison population was
only simulated in age groups 15 years and above.
Simulation of the health care system
The rate of TB detection by the health care system was calculated
such that the proportion of cases detected was determined by the
reported time-variant case detection rate. Treatment outcomes
were divided into (1) success, (2) death and (3) unfavourable out-
comes other than death. The probability of reaching each of these
three outcomes was time-variant, parameterised according to
WHOdata and differed according to the patient’s treatment history.
Calibration
We calibrated the model by adjusting five important but uncertain
epidemiological parameters to align with Bulgaria’s reported TB
Fig. 1. Epidemiological calibration results. The blue shaded areas represent model estimates. The black lines and hatched areas are mean values and confidence
limits, respectively, for indicator data from the WHO Global TB report (2016 and 2017). Data from the WHO Global TB Report 2017 were used for the years from
2000 to 2016. As the WHO Global TB Report 2017 did not report data prior to 2000, the WHO Global TB Report 2016 was used for data points for the years that
were not included in the 2017 report (1990 to 1999). The red lines in the Incidence panel indicate the WHO incidence data points against which the model was cali-
brated. Grey lines represent the SDG targets for 2030, the End TB Strategy targets for 2035 and the interimmilestones for 2020 and 2025. Units of all horizontal axes are
calendar years and units of vertical axes are: incidence, per 100 000 per year; mortality, per 100 000 per year; prevalence per 100 000; notifications, absolute number.
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incidence for the period 2010 to 2016 only, as the Bulgarian
National Tuberculosis Program (NTP) and country’s experts
considered estimates prior to 2010 to be less reliable. Model cali-
bration was further verified by comparing model predictions with
WHO estimates regarding prevalence and reported mortality.
Calibrated parameters were then used to project the future epi-
demiology under baseline conditions and different counterfactual
scenarios.
Interventions
In addition to the baseline conditions in which all time-variant
parameters were maintained at their 2016 values, we developed
a set of six programmatic interventions in collaboration with
the country’s NTP (Table 1). These interventions were designed
to represent real-world programmatic changes currently under
consideration by the Bulgarian NTP. The interventions were
modelled by varying relevant model parameters from their base-
line values, with the changes informed by reviews of the literature
(undertaken by JMT, TND, RR and ESM). Two authors (JMT and
TND) assessed the standard of evidence for the interventions
implemented blinded to each other’s assessments, with complete
agreement between the two blinded assessments.
For the purpose of discussion below, we also present an unreal-
istic scenario which represents complete cessation of all transmis-
sion of Mtb from 2017 onwards with other parameters as for the
baseline scenario.
Economics
A logistic relationship was used to estimate the expected costs
incurred from a given level of coverage of each intervention and
the size of the population targeted by that intervention, as previ-
ously described [8]. Logistic functions can allow coverage to
saturate at high-spending levels, thus better reflecting program-
matic reality. Start-up costs for each new intervention simulated
were applied separately and spread over the initial years for
which that intervention was implemented. The economic inputs
estimated in collaboration with the Bulgaria NTP are presented
Fig. 2. Predicted effect of interventions on overall epidemic. Black, baseline; thin grey, the SDG targets for 2030, the End TB Strategy targets for 2035 and the
interim milestones for 2020 and 2025; light blue, short course regimen for MDR-TB (Scenario 1); yellow, scale-up DST coverage in culture-positive TB cases
(Scenario 2); green, scale-up food vouchers for all patients under treatment (Scenario 3); purple, discontinue Open Doors program (Scenario 5); orange, discontinue
NGO activities (Scenario 6); thick grey, combination of scenarios 1, 2, 3 and 4 (Scenario 7); dashed black, all transmission completely ceases from 2017 onwards.
Note that transitioning from inpatient care to ambulatory care for smear-negative and extrapulmonary DS-TB patients (Scenario 4) is not shown in the Figure as it
overlaps with the baseline, given the assumption that the two models of care have comparable health outcomes. Scenario 2 also closely overlaps baseline (in its
impact on all forms of TB) and so is not visible. Units of all horizontal axes are calendar years and units of vertical axes are: incidence, per 100 000 per year; mor-
tality, per 100 000 per year; prevalence per 100 000; notifications, absolute number.
4 T. N. Doan et al.
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in Supplementary Table S2 and the cost-coverage curves are
presented in Supplementary Figure S16.
Results
Calibration and predicted epidemic trajectory
Figure 1 presents the epidemiological predictions obtained from
the automatic calibration process described above. Although TB
incidence was the only indicator targeted during calibration, the
predicted values of prevalence and notifications also closely
matched WHO’s reported estimates for the recent years; while
the model suggested that mortality may be under-reported, par-
ticularly in the most recent estimates. Despite the remarkably
close calibration to multiple indicators without any attempt to
target them, the evolution of the TB epidemic over time was less
closely matched, with the rate of decline in burden over recent
years not fully captured through the incorporation of time-variant
programmatic parameter fit to country-specific data alone. Given
that Bulgaria is a low-transmission setting, it may be that the
model’s slow decline in disease burden is a closer reflection of real-
ity than the more variable reported programmatic estimates or that
non-programmatic factors (e.g. improvements in general living
conditions) are also playing a role. The model predicted that
none of the targets set for incidence and mortality in 2025 and
2035 would be achieved under current programmatic conditions.
Predicted intervention effectiveness
The predicted impact of the simulated interventions on the overall
TB epidemic is presented in Figure 2, on specific risk groups in
Figure 3 and on the MDR-TB epidemic specifically in Figure 4.
Shifting to a short course regimen for MDR-TB is predicted to
have the greatest impact on MDR-TB prevalence and mortality
specifically, although the impact on the overall epidemic is negli-
gible due to the small proportion of all cases contributed by this
strain. Expanding coverage of DST has a negligible effect on over-
all burden and a modest reduction in MDR-TB mortality, due to
its already comprehensive coverage. Scaling up the food voucher
intervention has the greatest positive effect on overall mortality
Fig. 3. Predicted effect of interventions on disease burden in population risk groups. Black, baseline; light blue, short course regimen for MDR-TB (Scenario 1);
yellow, scale-up DST coverage in culture-positive TB cases (Scenario 2); green, scale-up food vouchers for all patients under treatment (Scenario 3); purple, dis-
continue Open Doors program (Scenario 5); orange, discontinue NGO activities (Scenario 6); thick grey, combination of scenarios 1, 2, 3 and 4 (Scenario 7); dashed
black, all transmission completely ceases from 2017 onwards. Note that transitioning from inpatient care to ambulatory care for smear-negative and extrapulmon-
ary DS-TB patients (Scenario 4) is not shown in the Figure as it overlaps with the baseline, given the assumption that the two models of care have comparable
health outcomes. No risk refers to the remainder of the population not belonging to one of the three simulated risk groups. Units of all horizontal axes are calendar
years and units of all vertical axes are events per 100 000 per year.
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of any intervention, and also has a marked positive effect on
MDR-TB mortality. This intervention is predicted to reduce over-
all TB mortality to 3.03 deaths per 100 000 per year in 2035 (vs.
3.71 under baseline conditions). Discontinuing the Open Doors
program would markedly affect TB burden indicators, increasing
incidence by 5.7% in 2035 relative to baseline conditions.
Discontinuation of all NGO activities has a comparable effect to
that of stopping the Open Doors program, with additional adverse
effects on Roma communities. Under either the cessation of Open
Doors or the cessation of all NGO activity scenario, notifications
would fall due to decreased case detection, masking the true
impact of these programmatic changes. Combining interventions
1, 2, 3 and 4 would modestly reduce overall TB incidence by 0.3%
and substantially reduce mortality by 20% in 2035 compared to
baseline. However, under such an ambitious scenario, the country
would still fall short of meeting the End TB Strategy targets.
Costs
The results of the economic analysis are shown in Table 2 and
Figure 5. Scale-up of phenotypic DST availability from 86 to
100% and expansion of the food voucher program to all patients
under treatment are both found to be highly affordable interven-
tions, with total programmatic costs below € 100 000 per year.
Short course MDR-TB treatment was markedly cost-saving.
Shifting from the existing model of primarily inpatient care to a
predominantly ambulatory approach for non-smear-positive
patients would result in considerable cost savings.
Discussion
We project that continuing the current programmatic TB
response in Bulgaria will result in a steady but modest decline
in overall disease burden. This would fall far short of meeting
the country’s ambitious targets for mortality and incidence for
2025 or global targets for both indicators for 2035. Food vouchers
for all patients under treatment are likely to have the greatest
impact on reducing TB burden, and in particular TB mortality.
The discontinuation of NGO activities and the Open Doors pro-
gram would result in a considerable increase in both overall TB
and MDR-TB burden. Therefore, maintaining these two interven-
tions is necessary to sustain the progress in TB control that has
been made in the country. We also found that ambulatory care
is cost saving while having no impact on epidemiology of TB,
Fig. 4. Predicted effect of interventions on the burden of MDR-TB. Black, baseline; light blue, short course regimen for MDR-TB (Scenario 1); yellow, scale-up DST
coverage in culture-positive TB cases (Scenario 2); green, scale-up food vouchers for all patients under treatment (Scenario 3); purple, discontinue Open Doors
program (Scenario 5); orange, discontinue NGO activities (Scenario 6); thick grey, combination of scenarios 1, 2, 3 and 4 (Scenario 7); dashed black, all transmission
completely ceases from 2017 onwards. Units of all horizontal axes are calendar years and units of vertical axes are: MDR-TB incidence, per 100 000 per year;
MDR-TB mortality, per 100 000 per year; MDR-TB prevalence per 100 000; notifications, absolute number; MDR-TB percentage incidence, percentage.
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Table 2. Predicted epidemiological and financial outcomes of interventions
Intervention
TB incidence in 2035 MDR-TB incidence in 2035 TB mortality in 2035 Mortality MDR in 2035
Additional
intervention
costs or savings
Per 100 000 per year
Relative change
(%)
Per 10 000 000 per
year
Relative change
(%)
Per 100 000 per
year Relative change (%) Per 100 000 per year Relative change (%) € per year
Baseline 26.17 Reference 35.85 Reference 3.71 Reference 0.184 Reference Reference
1. Short course
regimen for MDR-TB
26.16 (26.16 to 26.16) −0.0 (−0.0 to −0.0) 35.36 (35.30 to 35.42) −1.4 (−1.5 to −1.2) 3.69 (3.69 to 3.70) −0.6 (−0.8 to −0.4) 0.144 (0.137 to
0.151)
−21.6 (−25.2 to
−17.7)
−42 115
2. Scale-up DST
coverage
26.14 (25.99 to 26.28) −0.1 (−0.7 to 0.4) 35.18 (34.62 to 35.87) −1.9 (−3.4 to 0.1) 3.69 (3.63 to 3.75) −0.4 (−2.0 to 1.2) 0.175 (0.170 to
0.181)
−4.5 (−7.3 to −1.0) 40 942
3. Scale-up food
vouchers to reach all
patients under
treatment
26.12 (26.11 to 26.13) −0.2 (−0.2 to −0.1) 35.25 (35.10 to 35.38) −1.7 (−2.1 to −1.3) 3.03 (2.86 to 3.19) −18.4 (−22.9 to
−14.2)
0.168 (0.164 to
0.172)
−8.5 (−10.5 to −6.5) 61 756
4. Ambulatory care
for smear-negative
and extrapulmonary
DS-TB
No change No change No change No change No change No change No change No change −498 514a
5. Discontinue Open
Doors
27.67 (27.08 to 28.27) +5.7 (3.5 to 8.0) 38.77 (37.64 to 39.89) +8.1 (5.0 to 11.2) 4.63 (4.27 to 5.00) +24.5 (14.9 to 34.6) 0.195 (0.191 to
0.200)
+6.2 (3.8 to 8.6) NA
6. Discontinue NGO
activities
28.24 (27.42 to 29.14) +7.9 (4.8 to 11.4) 39.71 (38.23 to 41.30) +10.8 (6.6 to 15.2) 4.79 (4.38 to 5.27) +29.0 (18.1 to 42.0) 0.198 (0.193 to
0.204)
+7.7 (4.8 to 11.1) NA
7. Combined (1, 2, 3
and 4)
26.08 (25.95 to 26.23) −0.3 (−0.8 to 0.2) 34.25 (33.61 to 34.89) −4.4 (−6.2 to −2.7) 2.97 (2.82 to 3.18) −20.1 (−24.1 to
−15.5)
0.124 (0.112 to
0.134)
−33.0 (−39.1 to
−26.5)
−434 154
DS, drug-susceptible; DST, drug susceptibility testing; MDR, multidrug-resistant; NA, not applicable; NGO, non-governmental organisation; TB, tuberculosis.
The ranges reported in brackets are the 95% simulation intervals obtained when incorporating uncertainty by using 50 samples from a Latin hypercube sampling approach to vary the parameters characterising the intervention effects only (while
holding all epidemiological values to their calibrated values).
aPredicted difference between the annual cost of ambulatory care (439 308€ per year) and the annual cost of current care programs (937 822€ per year) for smear-negative and extrapulmonary patients.
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and that short course therapy for MDR-TB is both cost saving
and reduces MDR-TB burden. Under an ambitious scenario in
which interventions 1, 2, 3 and 4 are combined, overall TB and
MDR-TB burden would decline substantially; however the End
TB Strategy targets would still not be achieved.
Bulgaria is considering a transition from hospital-based TB
management to a comprehensive ambulatory TB care program.
Previous studies have consistently shown that there is no signifi-
cant difference in treatment outcomes between the two models of
care [22, 25]. Consistent with this, in our model we simulate no
parameter changes as a consequence of changing to this approach.
Nevertheless, from an individual patient’s perspective, evidence
suggests that ambulatory care is preferable to hospital-based
care by most patients [24]. In our economic analysis, we found
that ambulatory care was cheaper than hospital-based care
(hence cost-saving) and so is a logical programmatic choice.
In our economic analysis of replacing the conventional
MDR-TB regimen with a short-course regimen, we focused on
the financial impact of this change rather than on the overall
financial burden of MDR-TB. Although MDR-TB only accounts
for 1.2% of all TB cases in Bulgaria, its economic burden is likely
to be more substantial due to the much higher costs of diagnosis
and treatment. Assuming similar results can be achieved to those
observed in Bangladesh, Cameroon and Niger [16–18], we esti-
mate that replacing the conventional MDR-TB treatment regimen
with a short course approach would substantially reduce
MDR-TB burden and be cost-saving. As such, implementing a
short course regimen for MDR-TB and ambulatory care is antici-
pated to improve the efficiency of the TB program.
Our model simulates a low-transmission epidemic with most
TB cases arising from late reactivation of distantly acquired infec-
tions. Despite this, the simulated proportion of the population
with latent infection has declined only very slowly over recent
decades (Fig. S23), which is the explanation for the limited impact
of several interventions. Specifically, all programmatic changes
affect interventions directed at active cases and have no effect
on the latent pool. Figures 2–4 and Figure S24 show the predicted
epidemiological results of immediate and complete cessation of
transmission, indicating that incidence persists at considerable
rates long after this is implemented. Similarly, combining
Fig. 5. Comparison of baseline cost vs. scenario cost
for each intervention. All costs are yearly cost in
euros. Scenario 1, short course regimen for
MDR-TB; scenario 2, scale-up DST coverage in
culture-positive TB cases; scenario 3, scale-up food
vouchers for all patients under treatment; scenario
4, transitioning from inpatient care to ambulatory
care for smear-negative and extrapulmonary DS-TB
patients; scenario 7, combination of scenarios 1, 2,
3 and 4. Negative and positive cost values indicate
reduction and increase, respectively, of scenario
costs relative to baseline. Negative and positive per-
centages indicate reduction and increase, relatively,
of overall TB incidence (top panel) or overall TB
mortality (bottom panel) relative to baseline.
8 T. N. Doan et al.
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interventions 1, 2, 3 and 4 would still be insufficient for the
country to meet the End TB Strategy targets. These ambitious
scenarios highlight the importance of the pool of latent infection
in continuing to drive the epidemic in Bulgaria. Consistent with
this, previous studies have shown that addressing the pool of
LTBI through diagnosis and preventive treatment is critical to
achieving TB elimination [26–28].
To date, there remains a lack of strong evidence from
published literature on the epidemiological impact of scale-up
of DST coverage (intervention 2), Open Doors program (inter-
vention 5) and NGO activities (intervention 6). Given this, it is
important to balance the need to assess all real-world program-
matic interventions currently being considered by the Bulgarian
NTP against the standard of evidence available to inform each
intervention. Therefore, our philosophical approach was to pro-
vide estimates of all such interventions under consideration, but
also to highlight carefully the varying strength of evidence to sup-
port each one. To our knowledge, this has rarely been undertaken
in previous modelling studies, such that we believe this study
presents a significant advance over past programmatic modelling
studies in this respect. We obtained information about the impact
of these interventions from empirical data, in consultation with
the country NTP. Data gathering, synthesis and interpretation
were performed through in-country missions, in close consult-
ation with key country stakeholders. As such, we believe that
the model inputs for these interventions are as robust as possible,
but the estimates of the impact of each intervention should be
considered carefully in the context of the strength of the support-
ing evidence.
Although we represented TB transmission using a highly com-
plex model, limitations arising from this level of complexity
include that interpretation of every dynamic process occurring
within the model is impossible. This is offset by a more realistic
simulation of the epidemic’s characteristics, such as its concentra-
tion among risk groups. Despite this, the model also remains a
simplification of reality. For example, each simulation is deter-
ministic, such that stochastic fluctuations due to variation in
rates of transmission, reactivation or other processes are not cap-
tured. However, deterministic, compartmental models of TB
transmission dynamics are an established tool for estimating the
epidemic trajectory for TB at the country level and predicting
the impact of interventions [29]. For simplicity, persons with dia-
betes mellitus, the prison population and Roma communities
were considered to be mutually exclusive risk groups in our
model. While it is possible that an individual could simultan-
eously fall into more than one of these risk groups (e.g. being a
prisoner and having diabetes mellitus), allowing for this possibil-
ity would substantially increase the complexity of the model and
make it overly computationally expensive. In this study, the eco-
nomic analysis was conducted from a health provider perspective.
As such, we did not include patient costs such as travel costs, and
opportunity costs associated with time off work and income loss.
If a broader perspective, such as a societal perspective, was used
and these additional costs included, we anticipate that the eco-
nomic benefits of the food vouchers, ambulatory care and short-
course regimen for MDR-TB programs would appear even more
favourable.
The findings of this study are useful for strategic planning for
TB control in the country to ensure efficient and sustainable pro-
vision of TB care beyond the end of the Global Fund grant. At the
time of writing, the country was developing a financing mechan-
ism drawing state budget to fund the continuation of NGO
activities and the Open Door program, and the implementation
of ambulatory care program and short-course regimens for
MDR-TB treatment. As part of the transition to domestically-
funded care, the Bulgarian government has increased its budget
contribution for TB programs to more than 90%. Additional
initiatives are being undertaken to further improve the efficiency
and sustainability of TB programs. These include financing sys-
tem reform, the integration of TB services into general pulmonary
health services, the incorporation of TB care into the National
Health Map planning tool and the increased utilisation of the
health information system and quantitative analysis to inform
TB policy, to name a few.
In conclusion, if current programmatic responses are contin-
ued, we predict further gradual declines in TB burden in
Bulgaria, although these will be well short of the SDGs and End
TB Strategy targets. Finding and treating TB cases in high-risk
groups such as Roma communities through the activities of
NGOs and Open Doors program are important components of
reducing TB burden. Addressing the underlying burden of LTBI
will also be important if the country is to achieve its
disease-related goals.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268819001857.
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